Last $2.50 HKD
Change Today 0.00 / 0.00%
Volume 416.0K
As of 3:01 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

lansen pharmaceutical holdin (503) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/19/14 - $4.15
52 Week Low
02/12/15 - $2.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LANSEN PHARMACEUTICAL HOLDIN (503)

Related News

No related news articles were found.

lansen pharmaceutical holdin (503) Related Businessweek News

No Related Businessweek News Found

lansen pharmaceutical holdin (503) Details

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty prescription western pharmaceuticals for the treatment of rheumatic diseases in the People’s Republic of China and internationally. It operates in Specialty Pharmaceuticals, Plant Extract and Healthcare Products, and Other Pharmaceuticals segments. The company’s core rheumatic specialty prescription western pharmaceuticals comprise Pafulin, which includes total glucosides of white peony capsules; Tuoshu, a leflunomide tablet; and MMF. It also offers other pharmaceuticals that include Bazhen Keli, a gynecological product; Yinxingye Pian, Paracetamol orally disintegrating tablets, and Dingpeng Rugao; and Huperzine A capsules, Chanfukang Keli, Ganda Pian, Xinnaojian Jiaonang, Runing Pian, Jian'er Qingjie Ye, and Xiao'er Jianwei Tangjiang, as well as Chinese medicine extracts and healthcare products. In addition, the company distributes human-like collagen dressing products, which are used for the suppression and mitigation of skin inflammation responses caused by various reasons, such as dermatitis, sensitive skin, acne, and laser therapy under the Kefumei brand in China. The company was founded in 2001 and is headquartered in Ningbo, the People’s Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Holdings Limited.

850 Employees
Last Reported Date: 09/10/14
Founded in 2001

lansen pharmaceutical holdin (503) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: $179.0K
Compensation as of Fiscal Year 2013.

lansen pharmaceutical holdin (503) Key Developments

Lansen Pharmaceutical Holdings Co., Ltd Announces Interim Dividend for the Six Months Ended June 30, 2014, Payable on or Before October 24, 2014

Lansen Pharmaceutical Holdings Co. Ltd. announced that the Directors recommend the payment of an interim dividend of 9.54 cents per share for the six months ended June 30, 2014 compared to 8.34 cents per share a year ago, to the shareholders listed in the register of members of the company as at the close of business on October 3, 2014. The interim dividends will be distributed on or before October 24, 2014 to the shareholders.

Lansen Pharmaceutical Holdings Co., Ltd Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Lansen Pharmaceutical Holdings Co. Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported revenue of USD 55,370,000 against USD 46,407,000 a year ago. Profit from operations was USD 9,909,000 against USD 8,334,000 a year ago. Profit before income tax was USD 9,263,000 against USD 8,173,000 a year ago. Profit attributable to owners of the company was USD 7,298,000 or 1.8 US cents per basic and diluted share against USD 6,374,000 or 1.5 US cents per basic and diluted share a year ago. Net cash generated from operating activities was USD 2,834,000 against USD 2,056,000 a year ago. Purchase of property, plant and equipment was USD 1,034,000 against USD 1,400,000 a year ago. Purchase of intangible assets was USD 8,718,000 against USD 624,000 a year ago.

Lansen Pharmaceutical Holdings Co., Ltd to Report First Half, 2014 Results on Aug 29, 2014

Lansen Pharmaceutical Holdings Co., Ltd announced that they will report first half, 2014 results on Aug 29, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
503:HK $2.50 HKD 0.00

503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 503.
View Industry Companies

Industry Analysis


Industry Average

Valuation 503 Industry Range
Price/Earnings 10.6x
Price/Sales 1.3x
Price/Book 1.2x
Price/Cash Flow 10.6x
TEV/Sales 0.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANSEN PHARMACEUTICAL HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at